Guardant Health, Inc. (GH) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin (GAAP) | 65.50 percent | FY2026-Q1 |
| Earnings per Share (Non-GAAP) | 0.45 USD_per_share | FY2026-Q1 |
| Non-GAAP Gross Margin | 66.00 percent | FY2026-Q1 |
| Total Revenue Year-Over-Year Growth | 48.00 percent | FY2026-Q1 |
| Oncology Volume Year-Over-Year Growth | 47.00 percent | FY2026-Q1 |
| Licensing and Other Revenue | 2.1M | FY2026-Q1 |
| Oncology Tests | 79K | FY2025-Q4 |
| Shield Screening Tests | 38K | FY2025-Q4 |
| Biopharma and Data Revenue | 54.7M | FY2025-Q3 |
| Oncology Revenue | 184.4M | FY2025-Q3 |
| Screening Revenue from Shield Testing | 24.1M | FY2025-Q3 |
| Guardant360 Average Selling Price | 3K | FY2024-Q4 |
Back to GH overview · GH earnings · GH holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.